Focused On-demand Library for Sentrin-specific protease 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H4L4

UPID:

SENP3_HUMAN

Alternative names:

SUMO-1-specific protease 3; Sentrin/SUMO-specific protease SENP3

Alternative UPACC:

Q9H4L4; Q66K15; Q86VS7; Q96PS4; Q9Y3W9

Background:

Sentrin-specific protease 3, also known as SUMO-1-specific protease 3 or SENP3, plays a crucial role in protein modification processes. It specifically releases SUMO2 and SUMO3 monomers from sumoylated substrates, enhancing the transcriptional activation capability of MEF2D and facilitating the deconjugation of SUMO2 and SUMO3 from CDCA8. SENP3 acts as a redox sensor in the nucleoplasm, enhancing HIF1A transcriptional activity by desumoylating EP300. It is essential for rRNA processing and regulates the sumoylation status of ZNF148, contributing to the transactivation of ZNF148 target genes as part of the 5FMC complex.

Therapeutic significance:

Understanding the role of Sentrin-specific protease 3 could open doors to potential therapeutic strategies.